Gene

MYCL

MYCL proto-oncogene, bHLH transcription factor

Explore in graph →CI-GENE-00015963HGNC:7555 ENSG00000116990 NCBI 4610 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MYCL EXPRESSION1
I-BET151 + JQ1Substitutes	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1706 Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strong… (full text at CIViC) PMID 27276402 · Suzuki et al., 2016 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (25)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved25 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm	8

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
· Anticancer Drugs · 2016 · PMID 27276402 · validated civic_curation pubmed